ÂÜÀòÂÒÂ×

Dr. Rosales brings significant clinical experience as a proven leader in both biotech and pharmaceutical industries. Prior to joining Compass, Dr. Rosales held an executive position as Chief Development Officer for Sesen Bio. Prior to Sesen Bio, she served as Vice President, R&D at MacroGenics for four years, where she led a team advancing the clinical development of margetuximab. Earlier in her career, Dr. Rosales held various executive and senior clinical leadership roles with increasing responsibilities, at Merck and Eli Lilly, where she led label-expansion and registrational studies for pembrolizumab and ramicirumab, respectively, in a number of indications, including but not limited to, biliary tract cancer, gastric cancer, esophageal cancer, and hepatocellular carcinoma.

Dr. Rosales obtained her medical degree from Yamaguchi University and her PhD in tumor immunology from Kansai Medical University in Japan.